1. Trang chủ
  2. » Luận Văn - Báo Cáo

Báo cáo khoa học: Structural flexibility in Trypanosoma brucei enolase revealed by X-ray crystallography and molecular dynamics pdf

13 404 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 13
Dung lượng 444,95 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Our results show that sulfate may, unexpectedly, induce full closure of catalytic site loops whereas, conversely, binding of inhibitor phosphonoacetohydroxamate may leave open a tunnel f

Trang 1

revealed by X-ray crystallography and molecular dynamics Marcos V de A S Navarro1,*,‡, Sandra M Gomes Dias1,*,§, Luciane V Mello2,3,*,

Maria T da Silva Giotto1,†, Sabine Gavalda4,–, Casimir Blonski4, Richard C Garratt1

and Daniel J Rigden2

1 Instituto de Fı´sica de Sa˜o Carlos, Universidade de Sa˜o Paulo, Sa˜o Carlos SP, Brazil

2 School of Biological Sciences, University of Liverpool, UK

3 Northwest Institute for Bio-Health Informatics, University of Liverpool, UK

4 Groupe de Chimie Organique Biologique, Universite´ Paul Sabatier, Toulouse, France

Enolase (2-phospho-d-glycerate hydrolase, EC 4.2.1.11)

catalyses the reversible dehydration of

d-2-phospho-glycerate to phosphoenolpyruvate (PEP) and

partici-pates in both glycolysis and gluconeogenesis In common with most glycolytic enzymes, enolases from a wide variety of organisms, including Archaea, Bacteria

Keywords

crystal structure; drug design; enolase;

molecular dynamics; structural flexibility

Correspondence

D J Rigden, School of Biological Sciences,

Crown Street, University of Liverpool,

Liverpool L69 7ZB, UK

Fax: +44 151 7954406

Tel: +44 151 7954467

E-mail: drigden@liv.ac.uk

Website: http://www.liv.ac.uk/biolsci/

*These authors contributed equally to this

work

†Deceased

Present address

‡Laborato´rio Nacional de Luz Sı´ncrotron,

Campinas, SP, Brazil

§Department of Molecular Medicine,

College of Veterinary Medicine, Cornell

University, Ithaca, NY, USA

–Department of Molecular Mechanisms of

Mycobacterial Infections, Institut de

Phar-macologie et de Biologie Structurale, CNRS,

UPS (UMR5089), Toulouse, France

(Received 5 June 2007, revised 25 July

2007, accepted 3 August 2007)

doi:10.1111/j.1742-4658.2007.06027.x

Enolase is a validated drug target in Trypanosoma brucei To better charac-terize its properties and guide drug design efforts, we have determined six new crystal structures of the enzyme, in various ligation states and confor-mations, and have carried out complementary molecular dynamics simula-tions The results show a striking structural diversity of loops near the catalytic site, for which variation can be interpreted as distinct modes of conformational variability that are explored during the molecular dynamics simulations Our results show that sulfate may, unexpectedly, induce full closure of catalytic site loops whereas, conversely, binding of inhibitor phosphonoacetohydroxamate may leave open a tunnel from the catalytic site to protein surface offering possibilities for drug development We also present the first complex of enolase with a novel inhibitor 2-fluoro-2-phos-phonoacetohydroxamate The molecular dynamics results further encour-age efforts to design irreversible species-specific inhibitors: they reveal that

a parasite enzyme-specific lysine may approach the catalytic site more closely than crystal structures suggest and also cast light on the issue of accessibility of parasite enzyme-specific cysteines to chemically modifying reagents One of the new sulfate structures contains a novel metal-binding site IV within the catalytic site cleft

Abbreviations

EV, eigenvector; FPAH, 2-fluoro-2-phosphonoacetohydroxamate; PAH, phosphonoacetohydroxamate; PDB, protein databank; PEP,

phosphoenolpyruvate.

Trang 2

and Eukarya, are highly conserved [1] The catalytic site

is particularly well conserved, leading to broadly similar

kinetic parameters for enzymes of different origins [2,3]

The quaternary structure of enolase is typically a

homodimer, although some bacteria apparently contain

octameric enzymes [4,5]

Each subunit of enolase contains an eightfold b⁄ a

barrel domain preceded by an N-terminal a + b

domain [6] The catalytic site is contained completely

within a single subunit and lies at the interface of the

two domains: monomeric enolase is catalytically active

[7] Catalysis results from acid–base chemistry involving

a Lys-Glu dyad [8,9] Also essential is the binding of

two divalent metal ions to distinct sites: the first

‘con-formational’ site being required for substrate binding

and the second ‘catalytic’ site, occupied after substrate

has bound, stabilizing the reaction intermediate [6]

This ordered binding is accompanied by dramatic

rear-rangements of three protein loops lying near the

cata-lytic site Note that, although the conventional loop

nomenclature is maintained here, regular secondary

structure is sometimes present in these regions Briefly,

when the catalytic site is occupied by sulfate, phosphate

or phosphoglycolate, all three loops typically adopt an

open conformation, as seen, for example, in our

previ-ous Trypanosoma brucei enolase structure [10] When

occupied by substrate, or the

phosphonoacetohydroxa-mate (PAH) inhibitor, and two metal ions, the loops

are generally all in a closed conformation, as in some

yeast structures [11] Intermediate semiclosed

confor-mations have been observed when one metal ion is

absent or in some complexes with PEP [12,13]

As well as its key roles in glycolysis and

gluconeo-genesis, enolase, in common with other glycolytic

enzymes [14], has a remarkable number of

‘moonlight-ing’ roles in diverse organisms that are unrelated to its

catalytic activity [15] These include roles in the RNA

degradosome in Escherichia coli [16], as a structure

lens protein (s-crystallin) in the eye [17], as a

transcrip-tion factor in both animals [18] and plants [19] and, on

cell surfaces, as a receptor for plasminogen [15] In this

last role, the expression of enolase on the surface of

streptococci is particularly interesting, where its

inter-action with host plasminogen is presumed to facilitate

entry of the parasite into host tissues [20] Very

recently, the enolase of the trypanosomatid parasite

Leishmania mexicanahas also been detected on the cell

surface [21] A role for enolase as plasminogen

recep-tor in this organism is highly plausible because

inter-action between parasite and plasminogen has been

demonstrated [22]

Our interest in T brucei enolase [2,10] stems from

the promise of the glycolytic pathway as a target for

drugs against parasitic protozoa [23] With few excep-tions, homologues of the enzymes involved are present

in the human host, and a premium is placed on seek-ing and exploitseek-ing structural differences between para-site and host proteins Irreversible inhibition is particularly desirable because it would be impervious

to high substrate levels that could displace competitive inhibitors [23] Using parasite enzyme-specific residues (e.g lysines in both cases), selective inhibitors against aldolase [24] and phosphofructokinase [25] have been developed Despite bearing chemically reactive groups,

by combining high affinity and low reactivity, opti-mized inhibitors of this kind should have minimal effects on other proteins in vivo Indeed, a prodrug version of an aldolase inhibitor kills parasite cells without detectable cytotoxicity against human MRC-5 cells [26]

Like other glycolytic enzymes, T brucei enolase has been validated as a drug target: RNA interference of enolase in the bloodstream form of the parasite leads

to an effect on its growth within 24 h and death com-mences at approximately 48 h [27] Encouragingly, the same study also demonstrated that a reduction in eno-lase activity to approximately 15–20% of its original level was sufficient for cell death to occur This sug-gests that incomplete inhibition of this enzyme in vivo might prove sufficient for effective treatment The pres-ence of homologous enolase isoenzymes in the human host raises the complication of selectivity In this respect, enolase is not the best target because the para-site and host enzymes share 58% sequence identity Nevertheless, modelling showed that there are three particularly interesting T brucei enzyme residues, two cysteines (numbered 147 and 241) and lysine 155, near

to the catalytic site, which are not conserved in the human enzymes [2] (Fig S3) The chemical characteris-tics of the side chains of these residues offer the poten-tial for species-selective permanent target inactivation

by appropriately designed covalent inhibitors The

T brucei crystal structure suggested that the cysteines were almost entirely solvent inaccessible, yet, most sur-prisingly, at least Cys147 could be chemically modified

by iodoacetamide with consequent enzyme inhibition [10] In that crystal structure, Lys155 is pointed away from the catalytic site, being unfavourably positioned

to make additional interactions with a catalytic site-bound inhibitor

In the present study, we present six new enolase structures that enhance our understanding of the struc-tural and dynamic properties of the T brucei enolase catalytic site, which is essential for further drug design The new structures demonstrate that the enzyme can adopt three distinct catalytic site structures in the

Trang 3

sulfate-bound form, including one containing a novel

metal binding site Furthermore, they show structural

heterogeneity in their inhibitor-bound forms,

highlight-ing the potential to extend future inhibitors out of

the ligand-binding pocket We also present extensive

molecular dynamics simulations aiming to address how

the apparently buried cysteine residues achieve solvent

accessibility and show that Lys155 may indeed offer a

useful alternative possibility for covalent inhibition

Results and Discussion

Overview of the new structures

Characteristics and statistics of data collection and

refinement for the six new structures are presented in

Table 1 The crystal form is the same in each case,

namely the C2221 form previously reported [10],

although the precipitant used was PEG 1000 rather

than the PEG monomethylether 550 In the subsequent

analyses, we compare these structures with the

previ-ously published sulfate-bound structure, refined to

2.35 A˚, and containing Zn2+ions bound to sites I and

III [10], which we refer to here as sulfate_1 The new

structures, all obtained by co-crystallization, are all of

significantly better resolution than sulfate_1, in

partic-ular a complex with PAH inhibitor that diffracted well

to 1.65 A˚ In common with previous structures, from

T brucei and other organisms, a single Arg residue,

numbered 400 in T brucei, lies in the disallowed region

of the Ramachandran plot [10] Among the three

important catalytic site loops previously described (and

discussed further below), there is only one that makes

a crystal contact This involves Glu272 of loop 3, its

last residue and the most distant from the catalytic

site Thus, we can be confident that the conformations

observed represent readily achieved structures of the

native enzyme, rather than crystal packing artefacts In

our initial sulfate_1 structure, density did not allow for

chain tracing of two stretches, from Thr41-Gly42 and

Thr260-Pro266, regions that are frequently poorly

ordered in other enolase structures With the exception

of sulfate_2, all the structures presented here could be

unambiguously fully traced In sulfate_2, density did

not allow for the tracing of the polypeptide chain

between Asp251 and Gln273 inclusive As with

sul-fate_1, one or two artefactual residues preceding the

N-terminal Met of the natural sequence could be

traced in each new structure, and these result from

thrombin cleavage of the His-tag used in purification

(see Experimental procedures) In the three

inhibitor-bound structures, artefactual Zn2+ ions bound, with

partial occupancy (0.5–0.7), at the crystal packing

interface to residues ‘His0’ and Glu27, and to His283 from a crystal symmetry-related chain

The new structures are diverse in the contents of their catalytic sites, both in terms of substrate⁄ inhibitor and

in terms of bound metal (Table 1) The two new sulfate complexes and the previous sulfate-bound structure were all achieved at highly similar crystallization condi-tions (Table 1) As such, there is no clear explanation why they should differ in conformation (see below) and

we view their structural diversity as being the result of

‘freezing out’ of similarly accessible catalytic site conformations Substrate (PEP) and inhibitor (phos-phonoacetohydroxamate, PAH) [28] bind with their phospho and phosphono groups, respectively, occupy-ing the same position as that occupied by sulfate in the earlier sulfate_1 structure [10] Schematic diagrams of the interactions of inhibitors and metal ions with eno-lase are given in Fig S4 The binding mode of PEP seen is essentially the same fully closed conformation as that seen for yeast enolase [protein databank (PDB) code 1one][29] One PAH structure is also fully closed,

as in an earlier yeast complex (PDB code 1ebg) [11], whereas the second, as discussed below, represents a novel conformation for bound PAH Electron density maps for each complex are given in Fig S5

The novel compound 2-fluoro-2-phosphonoaceto-hydroxamate (FPAH), a derivative with a pKa value more resembling that of the phosphate of substrate PEP, was also synthesized and its complex determined

It is a competitive inhibitor of enolase which, despite its lower pKa value compared to PAH, binds more poorly with a Ki at pH 7.2 of 1.4 lm compared to approximately 15 nm for PAH (see supplementary Doc S1 and Figs S1 and S2) [30] It binds in the same way as PEP and PAH with an electron density suggest-ing that both isomers of the R,S racemic mixture bind equally well (Fig S5) Despite the uniformity of ligand binding, protein structure varies considerably at the active site in the new set of structures Rather than try

to explain their differences in the typical qualitative way (i.e open, closed, semiopen, loose, etc.), we attempt a more quantitative description

As shown in Figs 1 and 2, the principal conforma-tional differences between the structures lie in three catalytic site loops, 1–3, corresponding to those high-lighted in many other studies However, unlike the results obtained in a similar analysis for Saccharo-myces cerevisiae crystal structures (data not shown), a fourth peak for the region from residues 215–220 is present This loop is a neighbour of loop 2 and moves

in a coordinated way in T brucei but not in yeast structures Because loop 4 is distant from the catalytic site, it is not discussed further

Trang 4

Rmerge

Rfree

2 )

a See

b Values

c Calculated

Trang 5

Borrowing a technique more commonly associated with molecular dynamics studies, we analysed the con-formational differences in the new set of structures using essential dynamics [31] This also allowed us to visualize to what extent the resulting modes of confor-mational variability were explored during molecular dynamics simulations (see later) The positions of the six new structures projected onto eigenvectors (EVs) 1 and 2 are shown in Fig 3A Visual inspection of the maximum and minimum projections of EV1 shows

A

B

Fig 3 (A) Projections of the six new crystal structures and molec-ular dynamics trajectories on to EVs 1 and 2 resulting from the essential dynamics analysis Blue circles are used for sulfate struc-tures [open for sulfate_1* (see Experimental procedures), filled for sulfate_3], green triangles for PAH complexes (open for PAH_1, filled for PAH_2), a magenta square for the PEP structure and an orange diamond for the FPAH complex Black dots mark the PEP + 2 Mg trajectory and red dots the single Mg trajectory start-ing from the same PEP complex protein conformation Dots are shown at 2 ps intervals along the trajectory (B) Path of the single

Mg trajectory, indicated at 20 ps intervals, showing a structural switch at approximately 5 ns from a closed (low values for EVs 1 and 2) to an open structure (high EVs) The trajectory start is marked with a circle whereas the end is indicated by a square.

Fig 2 Comparison of sulfate_1, sulfate_2, PEP and PAH_1

struc-tures, coloured, respectively, in shades of green, blue, magenta

and orange The FPAH ligand position closely resembles that of

PAH_1 A complete cartoon representation of sulfate_2 is shown.

Backbone structure is shown for the other three structures only for

loops 1–4, which are labelled Note the gaps in loops 1 and 3 of

the sulfate_1 structure and the loop 3 gap in the sulfate_2

struc-ture Side chains of Lys155 and His156 are shown as sticks, as are

the structures’ respective ligands showing the overlay of bound

sul-fate with phospho and phosphono groups Zinc atoms are shown

as spheres occupying the labelled sites I–IV Black dashes mark

the hydrogen bonding interactions of His156 with PEP or with

met-als in sites III or IV in the sulfate_1 and sulfate_2 structures,

respectively.

Fig 1 Multi-rms plot of the enolase structures in Table 1 produced

with LSQMAN [56] The multi-rms value is defined as the rms value of

the distances between all unique pairs of Ca atoms for a given

resi-due Loops 1–4 (see text) are labelled Note that the value for a

section of loop 3 is artificially low in a stretch, coloured grey, for

which density did not allow tracing of the chain in either of the

open forms, sulfate_1 or sulfate_2.

Trang 6

that it captures the coordinated closure of loops 1–4

over the catalytic site The structure sulfate_2 (high

value of EV1 projection) has the loops in a fully open

conformation whereas, in the other structures, they

close over the active site EV2 splits this group of five

to two sets, with positive projection values signifying

structures in which His156 remains outside the

cata-lytic site, whereas negative values mean that His156

enters the site so that the enzyme achieves a

catalyti-cally competent conformation A comparison of

sul-fate_1, sulfate_2, PEP and PAH_1 structures is shown

in Fig 2

Unexpected variability in inhibitor complex

structures

Comparison of the substrate and inhibitor complexes

shows that the His156-out and His156-in structures are

equally represented, the former by PAH_1 and FPAH

and the latter by PEP and PAH_2 This appears to be

the first time that an enolase-PAH complex has

crys-tallised in a nonfully closed conformation The PAH_1

and PAH_2 structures were crystallised at different pH

values We therefore considered whether varying

charge on the phosphono groups of the substrate, with

which His156 interacts on entering the catalytic site,

could be responsible However, the negative charge on

the PAH phosphono group would be greater at

pH 6.5, at which the His-out structure was obtained,

compared to crystallization at pH 5.0 of the His-in

PAH structure Furthermore, a greater negative charge

would be expected on the phosphono group of FPAH

than of PAH due to the lower pKavalue of the fluoro

derivative, yet the FPAH structure was also His-out

The pKa of His165 is not known experimentally,

although an observed value of 5.9 has been ascribed

to it in the yeast enzyme [32] If this is true, then its

ionization state will also differ at pH values of 5.0 and 6.5 A greater attraction for bound PAH of the more positively charged His165 is consistent with the His-in structure observed at pH 5.0 (PAH_2) and the His-out PAH_1 structure observed at pH 6.5 However, con-sideration of the ionization state of His165 does not explain why the FPAH structure at pH 5.0 should be His-out There is no obvious explanation for this structural difference, leading to the conclusion that the His-in and His-out conformations may be similarly energetically favourable and perhaps only chance leads

to the freezing of one or the other in a given crystal The previously unsuspected existence of His-out inhibitor-bound conformations has important implica-tions for further ligand design In the fully closed, His-in conformation, the ligand is fully enclosed in a substrate-sized cavity with little potential for the design

of a larger inhibitor of better affinity or selectivity By contrast, as shown in Fig 4, the outward pointing His156 conformation leaves a tunnel open leading from the protein surface down to the bound ligand This allows ‘growing room’ for a catalytic site-bound inhibitor, enabling access to a larger number of target residues and hence increasing the chance of achieving selectivity for the parasite enzyme over the human counterpart

EV3 from the essential dynamics analysis splits the two His-out structures, PAH_1 and FPAH (data not shown) The difference between these can be described

as a localized twist of loop 2 containing His156 In this case, an explanation is forthcoming The fluorine atom

of one of the isomers of the racemic FPAH makes a close nonbonded contact (3.0 A˚) with Gln164, induc-ing a small displacement of the entire loop Although evidently non-natural, the existence of this loop con-formation emphasizes just how concon-formationally plas-tic the catalyplas-tic sites loops are

Fig 4 A tunnel leading to the catalytic site

is present in PAH_1 (left) but not in PAH_2 (right) A semitransparent surface is shown, uniformly coloured with the exception of the surface contributions from bound PAH (col-oured magenta), Lys155 (dark grey) and His156 (light grey) These residues and the ligand are shown as sticks.

Trang 7

Sulfate complexes and a novel metal binding

site IV

The protein conformation most similar to the sulfate_1

structure [10] is sulfate_2 (Table 1) to which 405 Ca

atoms could be fit with an rmsd of 0.4 A˚ and a

maxi-mum displacement of 2.0 A˚ at position 276, a surface

residue distant from the catalytic site Remarkably,

however, the sulfate_2 structure binds its two zinc ions

differently to sulfate_1 Both have fully occupied I

sites, the so-called conformational site [6], but

although sulfate_1 showed the position of the

inhibi-tory metal site III, the sulfate_2 structure reveals a

further novel metal-binding site IV at the enolase

catalytic site As with site III, the metal in site IV is

ligated by His156 but, whereas metal in site III is also

bound by Gln164, Glu165 and Glu208, His156 is the

only protein ligand of the metal in site IV (Fig 5)

Zinc ions bound by single protein ligands are

compar-atively rare in the Metalloprotein Database [33] but

there are several other examples The Zn2+ ion in

site IV is fully occupied and there appears to be no

doubt regarding the identity of this feature in the

elec-tron density map: there are no other components of

the crystallization solution that could be responsible

Additionally, anomalous scattering maps reveal clear,

although somewhat noisy, density for both metal sites

(Fig S6A) The density is similar to that observed for

the sulfur atoms of cysteine and methionine residues,

which have similar scattering power to zinc at the

wavelength used (1.54 A˚) (Fig S6B) The zinc ion in

site IV is further ligated by five solvent molecules with

interatomic separations of 1.75–2.20 A˚ (Fig 5) The B-factor of the metal ion in site IV of 41.3 is close to that of the ligating nitrogen atom of His156 (39.2) The His156 conformations in the sulfate_1 and sul-fate_2 structures differ by only 21 at the v1 rotation, but by a 180 flip of the imidazole ring because the Ne2 atom is involved in both cases (Fig 2) The occu-pation of site IV is unexpected because site III, with additional, negatively charged ligands, would be expected to have a higher affinity for the metal We can be confident that site III, and not site IV, corre-sponds to the inhibitory metal site characterized kineti-cally because the H156A mutant of the S cerevisiae enzyme retains an inhibitory site with one third of the native enzyme’s affinity [34] Such a mutant would simply lack a site IV because the His side chain con-tributes its only protein coordination Nevertheless, it remains possible that binding to site IV contributes to the inhibition of enolase at elevated metal concentra-tions

The sulfate_3 structure closely resembles the PEP and PAH_2 structures, with loops 1–4 fully closed Its

Ca atoms can be fit to those of the PEP complex to produce an rmsd of 0.23 A˚ Additionally, its two zinc ions in sites I and II superimpose on those of the PEP complex, as does the sulfate on the phospho group of PEP (Fig 2) It is unusual for occupation of the cata-lytic site by a small sulfate or phosphate to be suffi-cient to support full closure This situation was seen in one subunit of the E coli structure, but the influence

of crystal packing was suspected [35] More recently, one subunit of the asymmetric human neuron enolase

Fig 5 Coordination of zinc ions occupying

metal site I and novel site IV (labelled) in the

sulfate_2 structure Side chains and sulfate

are shown as sticks, water molecules and

grey, respectively Electron density from a

10 r is shown in magenta Density in a

1 r in the vicinity of site IV, and at 2 r

around the sulfate and metal site I.

Trang 8

was demonstrated to adopt the closed conformation

while containing only phosphate or sulfate [36]

Molecular dynamics simulations

The static description of crystal structures is

incom-plete for many proteins but particularly so in the case

of enolase Not only do multiple structures from

sev-eral species demonstrate large conformational changes

at the catalytic site but also, in the case of the T

bru-ceienzyme, crystal structures show Cys147 and Cys241

to be entirely buried in the second layer of protein

resi-dues below the base of the catalytic site [10] whereas

experimental data show that at least Cys147 can be

modified by iodoacetamide with resulting protein

inactivation [10] To explore this and other issues, we

carried out 10 ns duration molecular dynamics

simula-tions on two fully solvated dimeric enolase structures,

the PEP complex and a PEP structure derivative with

active site contents removed to leave a single divalent

metal ion, the ‘conformational’ ion in site I In each

case, Zn2+ was replaced by the more physiologically

relevant Mg2+

Initial modeling also highlighted Lys155 as a residue

near the catalytic site, present only in enolases from

T brucei and Leishmania major, Euglena gracilis and

Treponema pallidum, which could be a target for

irre-versible modification by a suitable inhibitor Such an

inhibitor would likely occupy the catalytic site; thus,

we assessed how closely the Lys155 side chain

approached ligands in that site In the previous

sul-fate_1 structure [10], the Nf atom of Lys155 was far,

around 12 A˚, from the catalytic site-bound sulfate In

the new PEP, PAH and FPAH structures, the Nf

atom is separated from the phospho(no) group by

approximately 7.5 A˚ Remarkably, although the

posi-tion of its neighbour, His156 varies dramatically

among these structures (Fig 2), the position of the Nf

atom is constant (Figs 2 and 4), making a hydrogen

bond with the backbone carbonyl of Ala39

Encourag-ingly, Lys155 lies at the mouth of the tunnel leading

from the protein surface to the bound ligand in the

His-out structures (Fig 4) As such, it would lie near

to an expanded inhibitor occupying that tunnel The

molecular dynamics results show that it approaches

the catalytic site even more closely The separations of

its Nf atom and the oxygen atoms of the PEP

phos-pho group were monitored throughout the PEP

trajec-tory and reached values as low as 6.5 A˚ Clearly, the

prospects for the exploitation of this parasite-specific

residue are much better than first supposed

To address the issue of Cys solvent accessibility, the

solvent-accessible surface area of Cys147 and Cys241

was monitored in both subunits throughout the molec-ular dynamics simulations It is already known that the presence of PEP or PAH does not affect the chemi-cal modification of the cysteines, suggesting that iodoacetamide and other reagents do not access the cysteines via the catalytic site Examination of the structures shows that the modifiable cysteine(s), and the adjacent conserved buried water molecules [10], lie quite close to the opposite surface of the protein Only the side chain of the penultimate residue, Trp428 sepa-rates them from bulk solvent The Trp side chain remains firmly in place throughout the course of our simulations, and neither buried water molecule exchanges with bulk solvent, but nevertheless transient displacement of the Trp side chain remains the most likely means of access to the cysteines by modifying reagents Given that modification is a slow process [10], it may be that the timescale of our simulations is simply too short for it to be observed Also, the actual presence of the rather hydrophobic reagents, rather than pure bulk solvent, may be necessary to induce the necessary structural alterations that allow access, as seen in other systems [37]

The trajectories were mapped onto the EVs obtained

by analysis of the crystal structures (Fig 3) to deter-mine to what extent these modes of structural variabil-ity are explored The PEP complex simulation remains

in the vicinity of the starting point There is little ten-dency toward the His156-out conformation (high val-ues of EV2) and no evidence at all of coordinated loop opening (high values of EV1) Because we have so far only observed the His156-out conformation with inhib-itors, and not with substrate, it may be that the His156-out is favoured only for the former ligands for reasons that remain unclear (see above) The results for the single Mg trajectory (obtained by removing PEP and the site II metal from the PEP complex struc-ture) are intriguingly different After exploring the neighbourhood of the starting conformation for approximately 5 ns, there is a transition (Fig 3B) and the protein explores an area of much higher values for both EV1 (centred around 0.6) and EV2 (centred around 0.2) This implies that, in the absence of PEP and site II metal, there is a shift towards a more open structure along both the coordinated loop dimension (EV1) and the His156-out dimension (EV2) The tra-jectory reaches the EV1 value of the open sulfate_1* structure (maximum 1.73) and exceeds the EV2 values

of the His156-out inhibitor complexes (maximum 0.45) These results are fully consistent with the pre-vailing notion of an ordered mechanism for enolase [38] With only metal site I occupied, the enzyme adopts an open conformation (high values of EVs 1

Trang 9

and 2) but with substrate present, and site II occupied

is stable in a closed conformation (lower values of EVs

1 and 2) in which catalytic residues align precisely for

reaction to occur The mapping of the trajectories onto

EV3 (not shown), confirms that the twisted His156-out

loop induced by the fluorine atoms in the FPAH is a

conformation not explored naturally and therefore an

unfavourable one This suggests that the lower pKa

value of that inhibitor, compared to parent PAH,

comes at an energetic cost, consistent with the higher

experimental Kiof FPAH (Doc S1, Figs S1–S2)

Conclusions

Although previous work has painted a picture of

flexi-ble loops near the enolase catalytic site, the diversity

of structures observed for the T brucei enzyme, in a

single crystal form and at broadly similar pH values, is

impressive Particularly notable are the findings that

sulfate occupation of the catalytic site alone can lead

to full closure of all loops whereas, for reasons

unknown, other sulfate-bound structures are open and

exhibit unexpected diversity of metal binding [10]

Sim-ilarly, occupation with the inhibitor PAH (or our

novel fluorinated PAH derivative) need not lead to full

closure of catalytic site loops, leaving open a tunnel

allowing for the design of enlarged inhibitors

occupy-ing more than the immediate vicinity of the small,

enclosed catalytic site Equally encouraging for future

drug design is the discovery that a potentially

modifi-able Lys155 side chain lies near to this tunnel, not far

from the catalytic site as previously supposed [10] Our

molecular dynamics results fail to demonstrate the

appearance of a channel exposing the modifiable

cyste-ine residue(s) to solvent, consistent with modification

being a slow process In summary, our results

empha-size the importance of a full understanding of the

dynamic properties of a drug target for the effective

design of tight-binding and specific ligands

Experimental procedures

Chemical synthesis

Phosphonoacetohydroxamate, lithium salt (PAH) and the

corresponding fluoro analog (FPAH) were obtained from

the diethylphosphonoacetic acid and the

diethyl-2-fluoro-phosphonoacetic acid, respectively, using an improved

reaction sequence distinct from that previously described

[28] Diethyl-2-fluoro-phosphonoacetic was obtained by

saponification of the triethyl-2-fluoro-phosphonoacetate

Diethylphosphonoacetic acid and the

diethyl-2-fluoro-phos-phonoacetic acid were linked to O-benzylhydroylamine in

the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodii-mide and 4-di(methylamino)pyridine [39] to obtain the pro-tected form of PAH and FPAH The next step consisted

of the deprotection of these compounds by a catalytic hydrogenation on Pd⁄ BaSO4[40] followed by the deprotec-tion of the phosphonate group by bromotrimethylsilane [41] Neutralization of the resulting acid derivatives with LiOH provided the expected products PAH and FPAH as lithium salts in 28% and 15% overall yield, respectively

X-ray crystallography

Recombinant T brucei enolase was expressed and purified

as previously described [2] Briefly, bacterial cells (E coli BL21(DE3)pLysS strain) harbouring the recombinant pET28a plasmid were grown at 37C until an attenuance (D) at 600 nm of approximately 0.5 was reached and protein expression was induced with 1 mm isopropyl thio-b-d-galac-toside for 20 h at 30C After centrifugation at 5000 g in a Sorvall RC26 plus centrifuge with Sorvall GS-3 rotor, the harvested cells were resuspended in TEA buffer, lysed through alternating cycles of freezing–thawing and then centrifuged The resulting clarified supernatant was directly subjected to nickel–nitrilotriacetic acid (Qiagen, Valencia,

CA, USA) affinity chromatography and the purified fusion protein was treated with thrombin to remove the His-tag Crystallization was carried out based on the reported conditions for T brucei enolase [2], but using PEG1000 as precipitant rather than PEG monomethylether 550 Ortho-rhombic C2221 crystals were obtained by the hanging drop method using a reservoir solution of 10% (w⁄ v) PEG1000, 0.01 m ZnSO4or ZnCl2, and 0.1 m Mes, pH 5.0–6.5, with

or without ligand at a concentration of 20 mm Before data collection, crystals of native T brucei enolase were immersed in the cryo-solution (mother liquor, 20% ethylene glycol) with or without 20 mm of ligand (PEP, PAH or FPAH) for 5 min and flash-cooled X-ray diffraction data were collected from two native crystals (referred to as sul-fate_2 and sulfate_3 in Table 1) and four ligand-cocrystal-lised crystals (referred to as PEP, PAH_1, PAH_2 and FPAH in Table 1) using a Mar345 image plate detector (X-Ray Research GmbH, Norderstedt, Germany) mounted

on a Rigaku UltraX 18 generator (Rigaku Corporation, Tokyo, Japan) or at the MX1 beam line at the Laborato´rio Nacional de Luz Sı´ncrotron (Campinas, Brazil) using Mar-CCD 125 mm detector and radiation at 1.431 A˚ (PAH_1) All data sets were processed and scaled with the software mosflm[42] and scala [43] from the ccp4 suite [44] The structures were straightforwardly solved by molecu-lar replacement with the software molrep [45], using the previously determined T brucei enolase structure (PDB code 1oep) as the search model The resulting molecular replacement solutions were subjected to interactive rounds

of manual rebuilding into 2Fo–Fc and Fo–Fc electron density maps using coot [46] and restrained refinement

Trang 10

implemented in refmac [47] The ligands were built into

difference electron density maps using coot As with the

pre-viously reported T brucei structure, intense positive peaks in

the difference maps were observed near the active site and

were modelled as metal ions Their identities and occupancy

were determined based on the resulting maps and B-factors

Water molecules were located automatically with the

pro-gram warp [48] An additional, partially occupied

(occu-pancy 0.5–0.7) and artefactual metal site involving a His

residue at position ‘0’ (i.e immediately preceding the natural

initiator Met within the tail downstream of the thrombin

cleavage site in the N-terminal extension containing the His

tag) was observed at a crystal lattice interface between in the

PAH and FPAH complexes In all cases, final rounds of

refinement were carried out with the entire subunit defined as

a translation⁄ libration ⁄ screw group in the modelling of

anisotropy within refmac Isotropic B-factors were

calcu-lated from the refined translation⁄ libration ⁄ screw parameters

and residual isotropic B-factors with tlsanl [49]

Stereo-chemical parameters were analysed with procheck [50]

Details of the data collection and refinement statistics are

shown in Table 1 The PDB [51] codes for the new structures

are: sulfate_2 (2ptw), sulfate_3 (2ptx), PEP (2pty), PAH_1

(1ptz), PAH_2 (2pu0) and FPAH (2pu1)

Molecular dynamics

Molecular dynamics simulations of 10 ns duration each were

performed on the PEP complex structure, and also a structure

in which the PEP and site II metal had been removed leaving

a single metal ion in site I The molecular dynamics

calcula-tions employed the gromacs simulation suite [52] using the

force field appropriate for proteins in water Sodium ions were

added to the simulation system to compensate for the net

neg-ative charge of the protein The simulation was carried out in

a cubic box with a minimal distance between solute and box

edge of 0.7 nm Periodic boundary conditions were used The

topology file for PEP was built using the small-molecule

topology generator prodrg [53], followed by manual

exami-nation The crystal structures were relaxed by the default

protocol of energy minimization and 100 ps of

position-restrained molecular dynamics, in which the protein is

restrained to its starting conformation, prior to the start of

the simulations proper After approximately 2000 ps of the

simulation proper, both trajectories were stable, fluctuating at

Ca rms deviations from the starting structure of

approxi-mately 0.18 nm (PEP + 2 Mg trajectory) and 0.22 nm (single

Mg trajectory) Monitoring of interatomic distances was

performed using other gromacs programs whereas solvent

accessible surface areas were calculated using dssp [54]

Other methods

Essential dynamics analysis [31] of a set of crystal

struc-tures (Table 1) was performed with programs from the

gromacs package [52] Because the sulfate_2 structure lacked a large number of loop 3 residues, it was omitted from the set However, the well-defined loop 1 of sulfate_2 was used to fill the gap of two residues (Thr41 and Gly42)

in the sulfate_1 structure, leaving only the gap in loop 3 from Thr260-Pro266 The sulfate_1 and sulfate_2 structures are similar overall and in the vicinity enabling a simple splicing of these two residues Limited energy minimization

of residues 40–43 of the result with modeller 9 [55] was carried out to regularize bond lengths and angles The spliced version of sulfate_1, called sulfate_1*, was used in the essential dynamics analysis The essential dynamics method is based on the diagonalization of the covariance matrix of atomic fluctuations, which yields a set of eigen-values and EVs The EVs indicate directions in a 3n-dimen-sional space (where n¼ the number of atoms in the protein) and describe concerted fluctuations of the atoms The eigenvalues reflect the magnitude of the fluctuation along the respective EVs Structural superpositions and other conformational analyses were performed using lsq-man [56] and mustang [57] Structural figures were made with pymol [58]

Acknowledgements

We are grateful to Paul Michels for useful discussions regarding this manuscript An early part of this work was supported by the European Commission through its INCO-DEV programme (contract ICA4-CT-2001-10075)

References

1 Fothergill-Gilmore LA & Michels PA (1993) Evolution

of glycolysis Prog Biophys Mol Biol 59, 105–235

2 Hannaert V, Albert MA, Rigden DJ, da Silva Giotto

MT, Thiemann O, Garratt RC, Van Roy J, Opperdoes

FR & Michels PA (2003) Kinetic characterization, structure modelling studies and crystallization of Try-panosoma bruceienolase Eur J Biochem 270, 3205– 3213

3 Qin J, Chai G, Brewer JM, Lovelace LL & Lebioda L (2006) Fluoride inhibition of enolase: crystal structure and thermodynamics Biochemistry 45, 793–800

4 Brown CK, Kuhlman PL, Mattingly S, Slates K, Calie

PJ & Farrar WW (1998) A model of the quaternary structure of enolases, based on structural and evolution-ary analysis of the octameric enolase from bacillus sub-tilis J Protein Chem 17, 855–866

5 Schurig H, Rutkat K, Rachel R & Jaenicke R (1995) Octameric enolase from the hyperthermophilic bacterium Thermotoga maritima: purification, characterization, and image processing Protein Sci 4, 228–236

Ngày đăng: 23/03/2014, 07:20

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm